New Haven, CT, United States of America

E Erik Johnson


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Work of E Erik Johnson in Viral Treatment

Introduction

E Erik Johnson, an accomplished inventor based in New Haven, CT, has made significant contributions to the field of virology through his patented work. With a focus on the treatment of pathogenic viruses, Johnson's innovative approach has the potential to impact countless lives.

Latest Patents

Johnson holds a noteworthy patent for "Rhabdoviruses with reengineered coats." This invention comprises replication-competent recombinant rhabdoviruses that lack a functional glycoprotein gene yet express foreign polypeptides, such as cellular receptors for other viruses. This unique method can be particularly useful in treating infections from pathogenic viruses. Specifically, one embodiment utilizes a recombinant vesicular stomatitis virus (VSV) that lacks its glycoprotein gene while expressing receptors related to HIV. This compelling approach allows for control of HIV infection in a T cell line by targeting and eliminating HIV-infected cells.

Career Highlights

E Erik Johnson is affiliated with Yale University, where he dedicates his efforts to research and innovation in the viral treatment sector. His work demonstrates a deep commitment to advancing scientific understanding and clinical applications of virology, particularly in combating HIV.

Collaborations

Johnson collaborates with eminent scientists such as John K Rose and Matthias Johannes Schnell. Through these collaborative efforts, he has been able to enhance the depth and breadth of his research, leading to groundbreaking discoveries in virology.

Conclusion

E Erik Johnson exemplifies the spirit of innovation in the field of virology. His patented work on reengineered rhabdoviruses stands as a testament to his commitment to addressing significant health challenges. By focusing on the treatment of pathogenic viruses, Johnson continues to contribute valuable insights that could reshape therapeutic strategies for viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…